

Formulary status report


Key metrics dashboard for NICE and AWMSG approved medicines since 01/01/2017

03/08/26

Total potential medicines to be
added to formulary


757

Number of medicines on formulary



Total number of medicines on formulary
Total number of medicines on formulary (<60 days)
Total number of medicines on formulary (<30 days)

Average time to implementation (days)



+4 More


04/06/26

Focusing on those medicines recommended >60 days ago, i.e. before:

Total potential medicines to be
added to formulary that were
recommended more than 60
days ago


734

Number of medicines on formulary



Recommended >60d ago - on formulary <60d
Recommended >60d ago - on formulary <30d

Average time to implementation (days)



+4 More

Medicines recommended >60 days ago

Medicine Name	Abbreviated Indication	Monitoring Start Date	Aneurin Bevan	BCU	Cardiff and Vale	Cwm Taf Morgannwg	Hywel Dda	Powys	Swansea Bay
Tofacitinib	Juvenile idiopathic arthritis	07/04/22	12	12	-	18	22	55	-
Risdiplam	Spinal muscular atrophy	14/01/22	144	13	20	5	3	27	0
Selpercatinib	Lung cancer	26/01/22	55	1	0	7	32	15	-
Osimertinib	Lung cancer	12/01/22	6	15	48	7	46	29	0
Pegcetacoplan	Paroxysmal nocturnal haemoglobinuria	09/03/22	27	26	29	47	51	15	0
Upadacitinib	Psoriatic arthritis	06/01/22	11	21	28	13	20	28	0
Pembrolizumab	Lung cancer	06/01/22	11	21	0	13	-	35	-
Odevixibat	Intrahepatic cholestasis	26/01/22	47	22	36	14	32	15	0
Pembrolizumab	Hodgkin lymphoma	21/01/22	17	6	41	12	37	20	0
Nivolumab	Renal cancer	03/02/22	0	14	-	5	56	7	-
Ipilimumab	Renal cancer	03/02/22	0	14	-	5	56	7	-
Dapagliflozin	Chronic kidney disease	03/02/22	-	14	28	6	56	7	-
Atidarsagene autotemcel	Metachromatic leukodystrophy	28/03/22	50	32	10	37	32	17	0

Please note:

This table is only displaying those medicines with an 'Monitoring Start Date' on or after January 1 2022

This table does not list medicines where the NICE recommendation has been retracted since its publication.

To view the full list of medicines, and their associated data for each health board, click here: [Formulary Status Report - Master Sheet](#)

Key

GREEN - On formulary. Where a number is stated this represents the number of days since the 'Monitoring Start Date' to formulary addition. '-' indicates that the medicine is already on formulary for the appraised indication.

YELLOW - On formulary. However the number of days stated is outside of the 60 day timescale.

WHITE - Not on formulary and within 60 days of approval date. Stated number is the number of days from 'Monitoring Start Date'.

RED - Not on formulary and outside of 60 days since approval date. Stated number is the number of days from 'Monitoring Start Date'.


PURPLE - Medicine is not yet being monitored for inclusion on health board formularies. Please see 'AWTTC Comments' in 'Formulary Status Report - Master Sheet' for more information.

04/06/26

Focusing on those medicines recommended <=60 days ago, i.e. on or since:

Total potential medicines to be added
to formulary that were recommended
within the last 60 days

17



Medicines recommended <60 days ago

Medicine Name	Abbreviated Indication	Monitoring Start Date	Aneurin Bevan	BCU	Cardiff and Vale	Cwm Taf Morgannwg	Hywel Dda	Powys	Swansea Bay
Avelumab	Renal cell carcinoma	11/06/26	0	15	1	11	-142	-181	-
Binimetinib	Non-small-cell lung cancer	29/06/26	0	24	0	4	22	-67	0
Givinostat	Duchenne muscular dystrophy	12/06/26	4	14	52	6	39	6	0
Nusinersen	Spinal muscular atrophy	12/06/26	3	14	52	6	39	-28	0
Cemiplimab	Lung cancer	07/07/26	6	14	27	1	21	3	0
Emicizumab	Haemophilia A	05/06/26	3	21	59	14	46	0	0
Seladelpar	Primary biliary cholangitis	04/06/26	60	22	60	15	47	5	0
Mirvetuximab soravtansine	Ovarian, fallopian tube or primary peritoneal cancer	04/06/26	5	22	15	8	47	5	0
Daratumumab	Multiple myeloma	21/07/26	0	0	13	13	13	3	0
Atogepant	Migraine	10/06/26	40	16	54	9	41	1	0
Pirtobrutinib	Lymphocytic leukaemia	16/06/26	34	10	48	6	35	0	0

Please note:

This table does not list medicines where the NICE recommendation has been retracted since its publication.

To view the full list of medicines, and their associated data for each health board, click here: [Formulary Status Report - Master Sheet](#)

Key

GREEN - On formulary. Where a number is stated this represents the number of days since the 'Monitoring Start Date' to formulary addition. '-' indicates that the medicine is already on formulary for the appraised indication.

YELLOW - On formulary. However the number of days stated is outside of the 60 day timescale.

WHITE - Not on formulary and within 60 days of approval date. Stated number is the number of days from 'Monitoring Start Date'.

RED - Not on formulary and outside of 60 days since approval date. Stated number is the number of days from 'Monitoring Start Date'.

PURPLE - Medicine is not yet being monitored for inclusion on health board formularies. Please see 'AWTTC Comments' in 'Formulary Status Report - Master Sheet' for more information.

Formulary status and time elapsed since NICE recommendation issued for medicines of special consideration

Medicine Name	Abbreviated Indication	Appraisal Approval Date	CAA Available Date	Aneurin Bevan	BCU	Cardiff and Vale	Cwm Taf Morgannwg	Hywel Dda	Powys	Swansea Bay
Strimvelis	Immunodeficiency	28/12/17		-	-	-	-	-	-	-
Spherox	Cartilage defects	12/01/18		3125	201	664	3125	3125	1601	-
Tisagenlecleucel	Leukaemia	16/11/18	16/11/18	2817	2817	1973	1977	0	1243	2007
Tisagenlecleucel	Lymphoma	01/02/19	01/02/19	2740	2740	517	1900	0	1166	272
Olaparib	Ovarian or fallopian tube or peritoneal cancer	29/11/19	08/01/21	111	11	0	26	24	12	-
Avatrombopag	Thrombocytopenia in liver disease	04/03/20		-246	-240	63	0	-191	-202	-246
Entrectinib	Lung cancer	15/06/20		-499	13	0	0	44	35	-520
Entrectinib	Solid tumours	25/06/20	17/11/21	-499	13	0	0	44	35	-
Semaglutide	Overweight and obesity	17/06/22		55	-174	-159	0	-137	-187	0

Please note:

This table does not list medicines where the NICE recommendation has been retracted since its publication.

To view the full list of medicines, and their associated data for each health board, click here: [Formulary Status Report - Master Sheet](#)

Key

GREEN - On formulary. Where a number is stated this represents the number of days since the 'Monitoring Start Date' to formulary addition. '-' indicates that the medicine is already on formulary for the appraised indication.

YELLOW - On formulary. However the number of days stated is outside of the 60 day timescale.

WHITE - Not on formulary and within 60 days of approval date. Stated number is the number of days from 'Monitoring Start Date'.

RED - Not on formulary and outside of 60 days since approval date. Stated number is the number of days from 'Monitoring Start Date'.